Trial Profile

A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2024 Results assessing Cellular and Proteomic Changes Following Administration of Peresolimab presented at the 25th Annual Congress of the European League Against Rheumatism
15 Nov 2023 Results assessing changes in exploratory biomarkers , presented at the ACR Convergence 2023.
03 Jun 2023 Results assessing the efficacy and safety of peresolimab in adult participants with moderate-to-severe rheumatoid arthritis, presented at the 24th Annual Congress of the European League Against Rheumatism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com